Citation Impact
Citing Papers
Crystal Structure and Mutational Analysis of Heparan Sulfate 3-O-Sulfotransferase Isoform 1
2004
Treatment of 51 pregnancies with danaparoid because of heparin intolerance
2004
Heparin-Protein Interactions
2002 Standout
Unilateral Chronic Thromboembolic Pulmonary Disease Associated With Combined Inherited Thrombophilia
2002
Platelet Count Monitoring and Laboratory Testing for Heparin-Induced Thrombocytopenia
2002
Affinity purification of heparin‐dependent antibodies to platelet factor 4 developed in heparin‐induced thrombocytopenia: biological characteristics and effects on platelet activation
2000
Incidence and clinical significance of anti‐PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin‐induced thrombocytopenia
2006
Prevalence of circulating procoagulant microparticles in women with recurrent miscarriage: a case-controlled study
2003
Mechanisms of Thrombus Formation
2008 Standout
Heparin-Induced Thrombocytopenia
2000
An international external quality assessment for laboratory diagnosis of heparin‐induced thrombocytopenia
2019
Heparin-induced thrombocytopenia
1996
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
High incidence of anti‐heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery
1998
Molecular Bases for Circadian Clocks
1999 Standout
Heparin‐induced thrombocytopenia: pathogenesis and management
2003
Laboratory Testing for Heparin-Induced Thrombocytopenia
2000
Treatment of Pulmonary Arterial Hypertension
2004 Standout
Congenital antithrombin III deficiency
1989
5 Thrombophilia: The Discovery of Activated Protein C Resistance
1995
Heparin‐induced thrombocytopenia: a prospective study on the incidence, platelet‐activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes
2007
Heparin-induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution
1997
Chronic thromboembolic pulmonary hypertension
2018
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Treatment and Prevention of Heparin-Induced Thrombocytopenia
2008 Standout
Antiphospholipid Syndrome and Heparin-induced Thrombocytopenia: Update on Similarities and Differences
2000
Malignancies, Prothrombotic Mutations, and the Risk of Venous Thrombosis
2005 Standout
HEPARIN‐INDUCED THROMBOCYTOPENIA IN DIALYSIS: Alternative Methods of Anticoagulation for Dialysis‐dependent Patients with Heparin‐induced Thrombocytopenia
2003
Temporal Aspects of Heparin-Induced Thrombocytopenia
2001 Standout
Pulmonary Microvascular Disease in Chronic Thromboembolic Pulmonary Hypertension
2006
Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men
1995 Standout
Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia
1999
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
2007 Standout
Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin
1996
Digestion and physiological properties of resistant starch in the human large bowel
1996
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
2008 Standout
Chronic thromboembolic pulmonary hypertension
2004
Thrombosis and ELISA optical density values in hospitalized patients with heparin‐induced thrombocytopenia
2004
Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism
2004 Standout
Chronic Thromboembolic Pulmonary Hypertension as an Uncommon Presentation of Primary Antiphospholipid Syndrome
2008
Factor VII activation and menopausal status
1990
Diagnostic score for heparin‐induced thrombocytopenia after cardiopulmonary bypass
2004
Pulmonary thromboendarterectomy surgery
2004
Epidemiology of the Antiphospholipid Antibody Syndrome
2000
What is the potential for overdiagnosis of heparin‐induced thrombocytopenia?
2007
Mutation in blood coagulation factor V associated with resistance to activated protein C
1994 StandoutNature
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
1993
Heparin-Induced Thrombocytopenia
2006 Standout
The Antiphospholipid Syndrome
2002 Standout
CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
2001
Serologic evidence of heparin sensitization in cancer patients receiving heparin flushes of venous access devices
1999
One-step production of lactate from cellulose as the sole carbon source without any other organic nutrient by recombinant cellulolytic Bacillus subtilis
2011
Risk factors for chronic thromboembolic pulmonary hypertension
2008
Molecular Biology of Chronic Thromboembolic Pulmonary Hypertension
2006
Regulation of LNS Domain Function by Alternative Splicing: The Structure of the Ligand-Binding Domain of Neurexin Iβ
1999 StandoutNobel
Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes
1996
Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension
2005
Heparin and Low-Molecular-Weight Heparin
1998
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
1999 Standout
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
2003 Standout
Effects of Iron Supplementation and Depletion on Hypoxic Pulmonary Hypertension
2009 StandoutNobel
Sickle-cell disease
2010 Standout
High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension
2003
Gut flora in health and disease
2003 Standout
Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease
1999
Pulmonary thromboembolic disease spectrum: diagnostic and therapeutic strategies
2009
The Cost-Effectiveness of Argatroban Treatment in Heparin-Induced Thrombocytopenia
2005
Safety of Warfarin Anticoagulation in Patients With Heparin-Induced Thrombocytopenia
1999
Complete antithrombin deficiency in mice results in embryonic lethality
2000
Chronic Thromboembolic Pulmonary Hypertension
2001
Exploring the Mechanism Responsible for Cellulase Thermostability by Structure-Guided Recombination
2016 StandoutNobel
Vascular-Bed–Specific Hemostasis and Hypercoagulable States
1999
Kinetic measurements and mechanism determination of Stf0 sulfotransferase using mass spectrometry
2005 StandoutNobel
Thrombophilic factors in chronic thromboembolic pulmonary hypertension
2001
Fibrinogen Aα Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension
2007
Risk Factors for Chronic Thromboembolic Pulmonary Hypertension
2006
World distribution of factor V Leiden
1995 Standout
Disseminated Intravascular Coagulation
1999 Standout
Splenectomy and chronic thromboembolic pulmonary hypertension
2005
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
Recurrent miscarriage
2006 Standout
Association of clinical features with HLA in chronic pulmonary thromboembolism
2005
Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature
2014
The increase in pulmonary arterial pressure caused by hypoxia depends on iron status
2008 StandoutNobel
Anticoagulant-induced skin necrosis in a patient with hereditary deficiency of protein S
1999
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Distinguishing between anti–platelet factor 4/heparin antibodies that can and cannot cause heparin‐induced thrombocytopenia
2015
Chronic thromboembolic pulmonary hypertension
2014
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions
1998
Thrombosis of the Cerebral Veins and Sinuses
2005 Standout
Increase in Thrombomodulin Concentrations After Pulmonary Thromboendarterectomy in Chronic Thromboembolic Pulmonary Hypertension
2003
Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor
2003
Fibrin Derived from Patients with Chronic Thromboembolic Pulmonary Hypertension Is Resistant to Lysis
2006
Perfusion Techniques for Pulmonary Thromboendarterectomy Under Deep Hypothermia Circulatory Arrest: A Case Series
2006
RISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSION
2001
Impact of the patient population on the risk for heparin-induced thrombocytopenia
2000 Standout
Antibodies From Patients With Heparin-Induced Thrombocytopenia/Thrombosis Recognize Different Epitopes on Heparin: Platelet Factor 4
1998
College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy.
1998
Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
2000
Human Urotensin II Is a Novel Activator of NADPH Oxidase in Human Pulmonary Artery Smooth Muscle Cells
2004
On the Prophylactic and Therapeutic Use of Danaparoid Sodium (Orgaran®) in Patients With Heparin-Induced Thrombocytopenia
2003
Regulation of Carbon Catabolism inBacillusSpecies
2000
Serpin Structure, Mechanism, and Function
2002 Standout
Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4–heparin antibodies to platelets and the resultant platelet activation
2000
Heparin-induced Thrombocytopenia: Towards Consensus
1998
Hemostatic Alterations in Sickle Cell Disease: Relationships to Disease Pathophysiology
2001
Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced Thrombocytopenia
1999
Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis
2004
Fondaparinux: A potential new therapy for HIT
2005
Pulmonary Arterial Hypertension
2006
Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study) [see comments]
1995
Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Thromboendarterectomy
2005
State-of-the-Art Review : Heparin-induced Thrombocytopenia and Thrombosis Syndrome
1998
Protease specificity and heparin binding and activation of recombinant protease nexin I.
1991
FcγRIIA H/R131 Polymorphism, Subclass-Specific IgG Anti-Heparin/Platelet Factor 4 Antibodies and Clinical Course in Patients With Heparin-Induced Thrombocytopenia and Thrombosis
1997
Pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension
2005
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Dissecting structure–function–stability relationships of a thermostable GH5-CBM3 cellulase from Bacillus subtilis 168
2011
Chronic Thromboembolic Pulmonary Hypertension
2006 Standout
Fermentation in the human large intestine and the available substrates
1987
The Hypercoagulable States
1985
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure
2007 StandoutNobel
Endothelial Hypoxia-Inducible Factor-2α Is Required for the Maintenance of Airway Microvasculature
2019 StandoutNobel
Intracellular Carbon Fluxes in Riboflavin-Producing Bacillus subtilis during Growth on Two-Carbon Substrate Mixtures
2002 StandoutNobel
First Workshop for Detection of Heparin-induced Antibodies: Validation of the Heparin-induced Platelet-activation Test (HIPA) in Comparison with a PF4/Heparin ELISA
1999
Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody
2002
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
2021 Standout
Low-Molecular-Weight Heparins
1997 Standout
Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic itinerary, resulting in retention of low-density lipoprotein on the cell surface
2002 StandoutNobel
Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
2000
Structure and function of the Bacillus hybrid enzyme GluXyn-1: Native-like jellyroll fold preserved after insertion of autonomous globular domain
1998
Venous thrombosis: a multicausal disease
1999 Standout
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
2021 Standout
Development of a Point of Care Lateral Flow Device for Measuring Human Plasma Fibrinogen
2010 StandoutNobel
Chronic thromboembolic pulmonary hypertension
2004
Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia
2001 Standout
Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis
2005 Standout
Argatroban Anticoagulation in Patients with Heparin-Induced Thrombocytopenia Requiring Renal Replacement Therapy
2005
Antibodies to Platelet Factor 4–Heparin After Cardiopulmonary Bypass in Patients Anticoagulated With Unfractionated Heparin or a Low-Molecular-Weight Heparin
1999
Factor VII and Fibrinogen Levels as Risk Factors for Venous Thrombosis
1994
Predictors of Outcome in Chronic Thromboembolic Pulmonary Hypertension
2007
Works of M. Wolf being referenced
Genes encoding xylan and -glucan hydrolysing enzymes in Bacillus subtilis: characterization, mapping and construction of strains deficient in lichenase, cellulase and xylanase
1995
Thrombotic risk factors in pulmonary hypertension
2000
New direct assay of free protein S antigen using two distinct monoclonal antibodies specific for the free form
1994
Clinical applications of a direct assay of free protein S antigen using monoclonal antibodies. A study of 59 cases
1994
Plasminogen activation by blood monocytes and alveolar macrophages in primary pulmonary hypertension
2002
Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia
1997
Comparison of Functional Assays for Protein S: European Collaborative Study of Patients with Congenital and Acquired Deficiency
1993
Homozygous Variant of Antithrombin III : AT III Fontainebleau
1986
Treatment of congenital antithrombin III deficiency with concentrates
1982
An Enzyme Immunoassay (ELISA) for the Quantitation of Human Factor VII
1986
Circulating Procoagulant Microparticles in Women with Unexplained Pregnancy Loss: a New Insight
2001
Partial Digestibility of Cooked Amylomaize Starch in Humans and Mice
1977
A new method for the estimation of protein C by ELISA
1984
Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia
1996
Decreased protein S activity in sickle cell disease.
1993
Antibodies to Macromolecular Platelet Factor 4-Heparin Complexes in Heparin-induced Thrombocytopenia: a Study of 44 Cases
1995
Prevalence of antiphospholipid-related antibodies in unselected patients with history of venous thrombosis
1998